Cardiac Progenitor Cells Guide

Overview

UCT-WJ-MSC–derived cardiac progenitors capable of differentiating into cardiomyocytes, endothelial cells, and smooth muscle cells; designed for myocardial regeneration after infarction or heart failure

FOR RESEARCH USE AND INTERNATIONAL USE ONLY | Not for clinical use in the United States

Source & Manufacturing
Derived from P2 UCT-WJ-MSCs via sequential cardiomyogenic differentiation
BMP-4 Activin-A (mesoderm induction), Wnt inhibition (cardiac specification), and thyroid hormone insulin maturation
DMSO-free cryopreservation
Post-thaw viability 95%
cGMP conditions
Markers: NKX2.5⁺, GATA4⁺, cTnI⁺ (cardiac troponin I), CD31⁺ (endothelial component), SMA⁺ (smooth muscle component)

Clinical Overview

Cardiac Progenitor Cells (CPCs) derived from UCT-WJ-MSCs provide a non-invasive, immune-compatible approach to myocardial regeneration. The adult heart has negligible regenerative capacity; following myocardial infarction (MI), irreversible cardiomyocyte death causes permanent scar formation and progressive heart failure. Akira CPCs address this through triple-lineage differentiation (cardiomyocytes, endothelial cells, smooth muscle cells) and a potent paracrine secretome. Delivered intracoronarily, intramyocardially, or intravenously, CPCs home to ischemic myocardium via SDF-1 gradients and exert both structural repair and functional improvement. Preclinical data show improved ejection fraction, reduced infarct size, and increased neovascularization. A multicenter RCT of WJ-MSC intracoronary infusion (n=116) demonstrated a clinically significant 7.8% absolute LVEF improvement at 18 months — establishing the clinical foundation for this product class.^[1]

Process

Mechanism of Action

Cardiomyocyte Differentiation: NKX2.5+ / cTnI+ differentiated cells can form sarcomeric structures, exhibit spontaneous calcium transients, and couple electrically with host cardiomyocytes via connexin-43 gap junctions — restoring mechanical synchrony in infarcted zones.

Angiogenesis & Neovascularization: VEGF, Ang-1, FGF-2 secreted by CPCs stimulate endothelial proliferation and capillary formation in ischemic myocardium. CD31+ endothelial derivatives directly incorporate into new microvascular networks.

Anti-Apoptotic Paracrine Effects: IGF-1, HGF, and Bcl-2 upregulation in border-zone cardiomyocytes reduces ischemia-induced apoptosis. MSC-sourced miR-21 in CPC exosomes directly targets PTEN, activating PI3K/Akt survival signaling.

Anti-Fibrotic Action: TGF-β pathway modulation, MMP secretion, and anti-fibrotic miRNAs (miR-146a, miR-let7) in CPC exosomes reduce scar expansion and prevent adverse ventricular remodeling.

Immunomodulation: Inherited MSC immune privilege suppresses excessive post-MI inflammation (which extends infarct size) via prostaglandin E2, IL-10, and IDO — without compromising essential inflammatory healing phases.

Biomarkers

Key Biomarkers & Molecular Cargo

Marker / Molecule	Functional Role
NKX2.5	Cardiac transcription factor — cardiomyocyte identity
GATA4	Cardiac lineage specification, sarcomere gene regulation
cTnI (Cardiac Troponin I)	Cardiomyocyte identity/function marker
Connexin-43 (Cx43)	Gap junction protein enabling electrical coupling with host cardiomyocytes
VEGF / Ang-1 / FGF-2	Pro-angiogenic factors for neovascularization
miR-21 / miR-146a	Exosomal anti-apoptotic and anti-fibrotic miRNAs
IGF-1 / HGF	Paracrine survival factors for border-zone cardiomyocyte protection
SDF-1 (CXCL12)	Homing signal; elevated in ischemic myocardium — guides CPC migration

Applications

Therapeutic Applications

Post-Myocardial Infarction (STEMI / NSTEMI) — acute and subacute myocardial repair
Congestive Heart Failure (CHF, both systolic & diastolic) — ejection fraction improvement
Ischemic Cardiomyopathy — neovascularization, anti-remodeling
Dilated & Hypertrophic Cardiomyopathy — structural support, anti-fibrotic
Cardiac Fibrosis — ECM remodeling, scar size reduction
Coronary Artery Disease — microvascular regeneration
Congenital Heart Defects — structural repair applications
Arrhythmias (post-ischemic) — connexin restoration, electrical synchrony
Post-surgical cardiac tissue repair

Evidence

Clinical & Preclinical Evidence

The pivotal multicenter RCT (NCT01291329, n=116 AMI patients) of intracoronary WJ-MSC infusion at 5–7 days post-reperfusion demonstrated LVEF improvement of 7.8 ± 0.9% vs 2.8 ± 1.2% in placebo at 18 months (P=0.001), with significant reductions in LV end-systolic and end-diastolic volumes — establishing WJ-MSCs as a superior alternative to bone marrow MSCs for cardiac regeneration.^[1]

A 2023 meta-analysis of HUC-MSC therapy in heart failure and MI (Cureus, PMID 38050512) systematically reviewed RCTs confirming improved LVEF and reduced adverse cardiac events with no safety signals — supporting the evidence base for allogeneic UCT-derived cardiac cell therapy.^[2]

A Phase III RCT (NCT05043610, Shiraz University) investigated WJ-MSC intracoronary delivery (1×10⁷ cells) in anterior STEMI patients to prevent heart failure. The completed trial used cGMP-grade WJ-MSCs in a single-blind, randomized design — directly analogous to the Akira CPC product specification.^[3]

In preclinical infarction models, UCT-MSC-derived CPCs improved ejection fraction by 12–18% at 4 weeks, reduced infarct scar size by 35–40%, increased capillary density 2.5-fold in the infarct border zone, and decreased apoptosis markers (TUNEL positivity) by 60% vs control.

The 2021 Stem Cell Research & Therapy meta-analysis covering 12 randomized trials of MSC transplantation post-MI confirmed a consistent 4–7% absolute LVEF improvement and 8–12% reduction in infarct size, with a favorable safety profile (no arrhythmia induction, tumor formation, or immune rejection).^[4]

Cardiac Progenitor Cells